MedTrace Logo

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

NCT00653419 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2008-04-04

No results posted yet for this study

Summary

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Conditions

  • To Determine Bioequivalence Under Fasting Conditions

Interventions

DRUG

buspirone HCl

Tablets, 30 mg, single-dose

DRUG

Buspar

Tablets, 30 mg, single-dose

Sponsors & Collaborators

  • Phoenix International Life Sciences, Inc.

    collaborator INDUSTRY

  • Par Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Samuel Serfaty, MD · Phoenix International Life Sciences, Inc.

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-06-30
Primary Completion
1998-09-30
Completion
1998-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00653419 on ClinicalTrials.gov